-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] With the intensive release of interim reports, the industry said that the pharmaceutical industry can pay attention to companies with better interim reports in the short te.
However, in the medium and long term, innovative products are expected to usher in policy support in the futu.
In addition, with the intensification of aging, the growth of the pharmaceutical industry is still very rig.
Analysts suggest focusing on three main lines: First, finding the "traversing medical insurance" variety is the k.
Second, the traditional Chinese medicine sector continues to benefit from the triple positives of “marginal policy + product price increase + reform of state-owned enterprises”, especially the relative benefits of traditional Chinese medicine consumer products and traditional Chinese medicine basic dru.
Third, the importance of independent and controllable industry chain is highlighted, especially the upstream of the pharmaceutical industry chain, including biopharmaceutical pharmaceutical equipment and consumables, life science products and services, imaging equipment,e.
In terms of individual stock opportunities, it is recommended to pay attention to Furui, Palin Bio, Shanghai Pharmaceuticals, Wuwu Bio, Dong E E Jiao, Chutian Technology,e.
Furui .
, L.
is a liver disease diagnosis and treatment enterprise in China, and its performance has ushered in an inflection poi.
The company's Fibroscan liver fibrosis diagnostic equipment has become a non-invasive immediate detection device for clinical liver fibrosis; the product, Compound Biejia Ruangan Tablet, is a recommended drug for liver fibrosis clinical guidelines, benefiting from the state's support for the traditional Chinese medicine industry and the company's out-of-hospital OTC mark.
Expansion is expected to become the main driver of performance; pediatric medical health management has the potential to expand the company's medical service busine.
Currently, three outpatient departments have been opened in Chengdu, and it is expected to gradually start to expand in different places in 202It is reported that Novo Nordisk recently announced that it will cooperate with Furui subsidiary Echosens to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and improve patients, medical providers and other stakeholders of the disea.
cogniti.
The research and development of new drugs for NASH is progressing, and the subsequent listing is expected to drive further expansion of the demand for liver fibrosis detecti.
There are many NASH patients, but there is no effective drug for the treatment of NASH in the domestic and foreign markets at present, and the lack of treatment methods inhibits the need for diagnos.
The main business of Perrin Biotech is the research, development, production and sales of blood produc.
In the past few years, the performance of Palin Bio has maintained rapid grow.
Analysts believe that there is still a lot of room for growth in the indust.
At present, Palin Bio has 38 pulping stations, including 27 pulping stations, 2 pulping stations in Shuanglin, Guangdong, which have been completed and awaiting acceptance inspection, and 9 pulping stations under construction in Paisfi.
In 2021, the amount of pulp collected is close to 900 tons, and in 2022, the amount of pulp collected is expected to exceed 1,000 tons, entering the first echelon of thousand-ton blood produc.
In recent years, Shanghai Pharmaceuticals has continued to increase R&D innovation on the basis of maintaining the steady growth of its existing busine.
In 2021, the number of new drug pipelines in the clinical application acceptance and follow-up research stages will reach 47, a substantial increase from the previous year, including 39 innovative drugs and 8 improved new dru.
As of 2022, the total number of new imported general generation products has been 5, and it will continue to maintain its status as the commercial general generation of imported innovative drugs, and provide one-stop management services for the entire supply chain of innovative products of global pharmaceutical compani.
Non-pharmaceutical businesses such as Shanghai medical equipment and big health continued to maintain a strong moment.
In addition, the company is scheduled to increase on April 8 and introduce Yunnan Baiyao as a strategic invest.
While optimizing the shareholding structure, it plans to combine the advantages of both parties to promote the common development of traditional Chinese medicine health and other businesses, and inject new momentum into the medium and long-term developme.
Wuwu Bio is a biopharmaceutical enterprise specializing in the research, development, production and sales of allergic disease diagnosis and treatment products, and is gradually promoting research and development in stem cells, natural medicines, medical artificial intelligence and other fiel.
It is reported that the scale of the desensitization diagnosis and treatment market in China continues to expand, and sublingual immunotherapy, as the first-line treatment for allergic rhinitis, has become more and more clinically accepted and recogniz.
The company relies on a professional academic marketing team to increase product promotion through multi-level academic conferences, and the effective market demand continues to gr.
The data shows that from January to June 2022, the total operating income of Wuwu Biology was 388,904,0048 yuan, a year-on-year increase of 188%; the net profit attributable to shareholders of the listed company was 181,137,5642 yuan, a year-on-year increase of 29
Dong'e Ejiao solidly promotes the "14th Five-Year" strategic plan, closely follows the strategic main line centered on consumer demand, continuously optimizes product structure, and upgrades product mix; profoundly practices the customer-centric digital operation model, deepens category extension and expansion and Innovation and exploration to achieve customer growth and performance improveme.
The company said that it will continue to focus on high-quality development, consolidate the position of "nourishing national treasure, Dong'e Ejiao" in the field of Chinese traditional medicine nourishing and health care, and further promote "value remodeling, business remodeling, organizational remodeling, and spiritual remodelin.
;Focusing on the development strategy of "reinforcing the foundation, extending the breakthrough, and innovating and exploring", consolidate the three core products and break through the functional health care category; provide solutions according to the needs of the market and customers, enhance the ability and innovation vitality of digital organizations, and continuously improve profitability ability and operating efficiency, and achieve healthy and healthy development of the compa.
The company expects that in the first half of 2022, the net profit attributable to the parent will be 270 million yuan to 340 million yuan, a year-on-year increase of 80%-12As a domestic pharmaceutical equipment enterprise, under the trend of import substitution and internationalization, Chutian Technology adheres to the strategy of "one vertical, one horizontal and one platform" to strengthen the front-end layout of pharmaceutical processes, and the driving force for performance growth continues to strength.
Some institutions predict the operating income in 2022-2024 They were 64 billion yuan, 95 billion yuan and 55 billion yuan respectively, and the net profit attributable to the parent company was 703 million yuan, 51 billion yuan and 061 billion yuan respective.
On July 10, 2022, the company announced that it plans to issue shares to purchase a total of 400% of the shares held by Ye Dajin and Ye Tiantian, the minority shareholders of the holding subsidiary Truking Feiyun Pharmaceutical Equipment (Changsha) .
, L.
Cloud will become a wholly-owned subsidiary of the listed compa.
It is reported that Truking Feiyun's products are an important part of the solid preparation pharmaceutical industry, and its market area is an important layout for listed companies to strengthen the entire industry chain in the futu.
It is an important step in further enriching the classification of listed companies in solid preparation pharmaceutical equipment products, so as to provide more technical solutions for the company's customer grou.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
However, in the medium and long term, innovative products are expected to usher in policy support in the futu.
In addition, with the intensification of aging, the growth of the pharmaceutical industry is still very rig.
Analysts suggest focusing on three main lines: First, finding the "traversing medical insurance" variety is the k.
Second, the traditional Chinese medicine sector continues to benefit from the triple positives of “marginal policy + product price increase + reform of state-owned enterprises”, especially the relative benefits of traditional Chinese medicine consumer products and traditional Chinese medicine basic dru.
Third, the importance of independent and controllable industry chain is highlighted, especially the upstream of the pharmaceutical industry chain, including biopharmaceutical pharmaceutical equipment and consumables, life science products and services, imaging equipment,e.
In terms of individual stock opportunities, it is recommended to pay attention to Furui, Palin Bio, Shanghai Pharmaceuticals, Wuwu Bio, Dong E E Jiao, Chutian Technology,e.
Furui .
, L.
is a liver disease diagnosis and treatment enterprise in China, and its performance has ushered in an inflection poi.
The company's Fibroscan liver fibrosis diagnostic equipment has become a non-invasive immediate detection device for clinical liver fibrosis; the product, Compound Biejia Ruangan Tablet, is a recommended drug for liver fibrosis clinical guidelines, benefiting from the state's support for the traditional Chinese medicine industry and the company's out-of-hospital OTC mark.
Expansion is expected to become the main driver of performance; pediatric medical health management has the potential to expand the company's medical service busine.
Currently, three outpatient departments have been opened in Chengdu, and it is expected to gradually start to expand in different places in 202It is reported that Novo Nordisk recently announced that it will cooperate with Furui subsidiary Echosens to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and improve patients, medical providers and other stakeholders of the disea.
cogniti.
The research and development of new drugs for NASH is progressing, and the subsequent listing is expected to drive further expansion of the demand for liver fibrosis detecti.
There are many NASH patients, but there is no effective drug for the treatment of NASH in the domestic and foreign markets at present, and the lack of treatment methods inhibits the need for diagnos.
The main business of Perrin Biotech is the research, development, production and sales of blood produc.
In the past few years, the performance of Palin Bio has maintained rapid grow.
Analysts believe that there is still a lot of room for growth in the indust.
At present, Palin Bio has 38 pulping stations, including 27 pulping stations, 2 pulping stations in Shuanglin, Guangdong, which have been completed and awaiting acceptance inspection, and 9 pulping stations under construction in Paisfi.
In 2021, the amount of pulp collected is close to 900 tons, and in 2022, the amount of pulp collected is expected to exceed 1,000 tons, entering the first echelon of thousand-ton blood produc.
In recent years, Shanghai Pharmaceuticals has continued to increase R&D innovation on the basis of maintaining the steady growth of its existing busine.
In 2021, the number of new drug pipelines in the clinical application acceptance and follow-up research stages will reach 47, a substantial increase from the previous year, including 39 innovative drugs and 8 improved new dru.
As of 2022, the total number of new imported general generation products has been 5, and it will continue to maintain its status as the commercial general generation of imported innovative drugs, and provide one-stop management services for the entire supply chain of innovative products of global pharmaceutical compani.
Non-pharmaceutical businesses such as Shanghai medical equipment and big health continued to maintain a strong moment.
In addition, the company is scheduled to increase on April 8 and introduce Yunnan Baiyao as a strategic invest.
While optimizing the shareholding structure, it plans to combine the advantages of both parties to promote the common development of traditional Chinese medicine health and other businesses, and inject new momentum into the medium and long-term developme.
Wuwu Bio is a biopharmaceutical enterprise specializing in the research, development, production and sales of allergic disease diagnosis and treatment products, and is gradually promoting research and development in stem cells, natural medicines, medical artificial intelligence and other fiel.
It is reported that the scale of the desensitization diagnosis and treatment market in China continues to expand, and sublingual immunotherapy, as the first-line treatment for allergic rhinitis, has become more and more clinically accepted and recogniz.
The company relies on a professional academic marketing team to increase product promotion through multi-level academic conferences, and the effective market demand continues to gr.
The data shows that from January to June 2022, the total operating income of Wuwu Biology was 388,904,0048 yuan, a year-on-year increase of 188%; the net profit attributable to shareholders of the listed company was 181,137,5642 yuan, a year-on-year increase of 29
Dong'e Ejiao solidly promotes the "14th Five-Year" strategic plan, closely follows the strategic main line centered on consumer demand, continuously optimizes product structure, and upgrades product mix; profoundly practices the customer-centric digital operation model, deepens category extension and expansion and Innovation and exploration to achieve customer growth and performance improveme.
The company said that it will continue to focus on high-quality development, consolidate the position of "nourishing national treasure, Dong'e Ejiao" in the field of Chinese traditional medicine nourishing and health care, and further promote "value remodeling, business remodeling, organizational remodeling, and spiritual remodelin.
;Focusing on the development strategy of "reinforcing the foundation, extending the breakthrough, and innovating and exploring", consolidate the three core products and break through the functional health care category; provide solutions according to the needs of the market and customers, enhance the ability and innovation vitality of digital organizations, and continuously improve profitability ability and operating efficiency, and achieve healthy and healthy development of the compa.
The company expects that in the first half of 2022, the net profit attributable to the parent will be 270 million yuan to 340 million yuan, a year-on-year increase of 80%-12As a domestic pharmaceutical equipment enterprise, under the trend of import substitution and internationalization, Chutian Technology adheres to the strategy of "one vertical, one horizontal and one platform" to strengthen the front-end layout of pharmaceutical processes, and the driving force for performance growth continues to strength.
Some institutions predict the operating income in 2022-2024 They were 64 billion yuan, 95 billion yuan and 55 billion yuan respectively, and the net profit attributable to the parent company was 703 million yuan, 51 billion yuan and 061 billion yuan respective.
On July 10, 2022, the company announced that it plans to issue shares to purchase a total of 400% of the shares held by Ye Dajin and Ye Tiantian, the minority shareholders of the holding subsidiary Truking Feiyun Pharmaceutical Equipment (Changsha) .
, L.
Cloud will become a wholly-owned subsidiary of the listed compa.
It is reported that Truking Feiyun's products are an important part of the solid preparation pharmaceutical industry, and its market area is an important layout for listed companies to strengthen the entire industry chain in the futu.
It is an important step in further enriching the classification of listed companies in solid preparation pharmaceutical equipment products, so as to provide more technical solutions for the company's customer grou.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
